Shaanxi Panlong Pharmaceutical Group Co., Ltd. (SHE:002864)

SHE:002864 Revenue

Shaanxi Panlong Pharmaceutical Group had revenue of 195.39M CNY in the quarter ending September 30, 2026, a decrease of -26.94%. This brings the company's total for the last twelve months to 917.38M, down -16.48% year-over-year. In the year 2025, Shaanxi Panlong Pharmaceutical Group had annual revenue of 1.14B with 17.15% growth. That makes Shaanxi Panlong Pharmaceutical Group the 20,289th largest company in the world by revenue and 3,729th in China.

• Revenue (ttm): 917.38M
• Revenue Growth: -16.48%
• P/S Ratio: 3.28
• Revenue / Employee: 990.70K
• Employees: 926
• Market Cap: 3.01B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Self-Produced Chinese Patent Medicine 644.11M 56.5%
• Pharmaceutical Commercial Distribution 254.08M 22.3%
• Chinese Herbal Pieces 235.00M 20.6%
• Other 5.53M 0.5%
• Health Products 2.14M 0.2%

Fiscal year ended Dec 31, 2025 See the full SHE:002864 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.14B	167.01M	17.15%
Dec 31, 2024	973.86M	-6.96M	-0.71%
Dec 31, 2023	980.83M	6.53M	0.67%
Jan 1, 2023	974.29M	86.81M	9.78%
Jan 1, 2022	887.48M	217.17M	32.40%

Data Source: S&P Global Market Intelligence Last updated: Oct 28, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 9, 2026

Data Sources Report a data error